DERIVADOS DE TRIAZOLDIACEPINA

NUEVOS COMPUESTOS DE FORMULA(I), EN LA QUE X ES - CH = CH - O S, R1 ES ALQUILO O ALCOXI DE CADENA CORTA O - CF3, R2 ES H, ALQUILO, ALCOXI O ALCANOILOXI DE CADENA CORTA OH, R3 Y R4 SON INDEPENDIENTEMENTE H, CL, F, ALQUILO O ALCOXI DE CADENA CORTA, R5 ES UN RADICAL DE FORMULA R6 - (CH2)N - C = C - O R7 - O - (CH2)M - C = C - (R6 Y R7 SON ARILO O UN RADICAL HETEROCICLICO, N ES UN ENTERO DE 0 A 2, Y M ES UN ENTERO DE 1 A 2), S ES UN ENTERO DE 0 A 1, CON LA CONDICION DE QUE CUANDO S ES 1 R2 NO ES H, ALCOXI O ALCANOILOXI, QUE CUANDO N ES 0, R6 DEBE ESTAR UNIDO A TRAVES DE UN ENLACE C - C, Y QUE R7 ESTE SIEMPRE UNIDO A TRAVES DE UN ENLACE C - O, Y CUIANDO HAY AL MENOS UN CENTRO ASIMETRICO, SUS ENANTIOMEROS Y RACEMATOS Y SALES DE ADICION DE ACIDO FARMACEUTICAMENTE ACEPTABLES, MUESTRAN ACTIVIDAD COMO ANTAGONISTAS DEL FACTOR ACTIVADOR DE PLAQUETAS Y SON POR ELLO UTILES EN ESTADOS PATOLOGICOS CARACTERIZADOS POR EXCESO DE FACTOR ACTIVADOR DE PLAQUETAS O PARA LA PREVENCION Y TRATAMIENTO DE NEFERMEDADESCARDIOVASCULARES, PULMONARES INMUNOLOGICAS, INFLAMATORIAS, DERMATOLOGICAS, ESTADOS DE SHOCK O RECHAZOS DE TRASPLANTES. The novel compounds of the general formula wherein X is -CH=CH- or S; R1 is lower alkyl, lower alkoxy or trifluoromethyl; R2 is hydrogen, lower alkyl, lower alkoxy, hydroxy or lower alkanoyloxy; R3 and R4, independently, are hydrogen, chlorine, fluorine, lower alkyl or lower alkoxy; R5 is a radical of the formula R6-(CH2)n-C IDENTICAL C- or R7-O-(CH2)m-C IDENTICAL C-, R6 and R7 are aryl or a heterocyclic radical; n is an integer from 0 to 2; m is an integer from 1 to 2 and s is an integer from 0 to 1; with the proviso that, when s is 1, R2 cannot be hydroxy, lower alkoxy or lower alkanoyloxy; that, when n is 0, R6 must be attached through a carbon to carbon bond, and that R7 is always attached through a carbon to oxygen bond, and, when at least one asymmetric centre is present, their enantiomers and racemates and pharmaceutically acceptable acid addition salts thereof exhibit activity as platelet activating factor (PAF) antagonists and are, therefore, useful in disease states characterized by excess platelet activating factor or for the prevention and treatment of cardiovascular diseases, pulmanory diseases, immunological disorders, inflammatory diseases, dermatological disorders, shocks or transplant rejections.